TNF-blocking therapies: an alternative mode of action? - PubMed (original) (raw)
Review
. 2005 Oct;26(10):518-22.
doi: 10.1016/j.it.2005.07.007.
Affiliations
- PMID: 16087401
- DOI: 10.1016/j.it.2005.07.007
Review
TNF-blocking therapies: an alternative mode of action?
Brian S W Choo-Kang et al. Trends Immunol. 2005 Oct.
Abstract
Despite expanding use of drugs blocking tumour necrosis factor (TNF), their precise mechanisms of action remain unclear. Early assumptions that they act by direct neutralization of the toxic inflammatory effects of TNF might be too simplistic because they explain neither the range of effects observed nor the varying properties of different TNF-blocking agents. Recent studies have demonstrated a key role for mast cell-derived TNF in the increase in lymph node size and the organizational complexity that accompanies a developing immune response. Regulation of this phenomenon might comprise a novel mode of action for TNF-directed therapy: by preventing this lymph node hyperplasia, TNF blockade could modulate immune responses, ameliorating pathology in autoimmune diseases, such as rheumatoid arthritis.
Similar articles
- Immunological therapies for rheumatoid arthritis.
Edwards CJ. Edwards CJ. Br Med Bull. 2005 Sep 20;73-74:71-82. doi: 10.1093/bmb/ldh051. Print 2005. Br Med Bull. 2005. PMID: 16174791 Review. - Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F, Murdaca G, Ghio M, Indiveri F. Puppo F, et al. Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016. Autoimmun Rev. 2005. PMID: 16214092 Review. - Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Hyrich KL, et al. Rheumatology (Oxford). 2006 Dec;45(12):1558-65. doi: 10.1093/rheumatology/kel149. Epub 2006 May 16. Rheumatology (Oxford). 2006. PMID: 16705046 - Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis.
Makrygiannakis D, Catrina AI. Makrygiannakis D, et al. J Rheumatol. 2012 Apr;39(4):679-85. doi: 10.3899/jrheum.110974. Epub 2012 Mar 15. J Rheumatol. 2012. PMID: 22422498 Review.
Cited by
- Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.
Pérez AR, Fontanella GH, Nocito AL, Revelli S, Bottasso OA. Pérez AR, et al. Clin Exp Immunol. 2009 Aug;157(2):291-9. doi: 10.1111/j.1365-2249.2009.03946.x. Clin Exp Immunol. 2009. PMID: 19604269 Free PMC article. - Treating very early rheumatoid arthritis.
Raza K, Buckley CE, Salmon M, Buckley CD. Raza K, et al. Best Pract Res Clin Rheumatol. 2006 Oct;20(5):849-63. doi: 10.1016/j.berh.2006.05.005. Best Pract Res Clin Rheumatol. 2006. PMID: 16980210 Free PMC article. Review. - Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases.
Sauzullo I, Scrivo R, Sessa P, Mengoni F, Vullo V, Valesini G, Mastroianni CM. Sauzullo I, et al. Sci Rep. 2018 May 18;8(1):7881. doi: 10.1038/s41598-018-26097-x. Sci Rep. 2018. PMID: 29777119 Free PMC article. - Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth.
Gounaris E, Tung CH, Restaino C, Maehr R, Kohler R, Joyce JA, Ploegh HL, Barrett TA, Weissleder R, Khazaie K. Gounaris E, et al. PLoS One. 2008 Aug 13;3(8):e2916. doi: 10.1371/journal.pone.0002916. PLoS One. 2008. PMID: 18698347 Free PMC article. - Modulation of tumor necrosis factor by microbial pathogens.
Rahman MM, McFadden G. Rahman MM, et al. PLoS Pathog. 2006 Feb;2(2):e4. doi: 10.1371/journal.ppat.0020004. PLoS Pathog. 2006. PMID: 16518473 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical